Previous reports have provided an excellent starting point for larger prospective studies of the clinical utility of circulating tumor DNA (ctDNA) and demonstrate that ctDNA may be a useful research tool for drug development, and the study of intratumor heterogeneity and clonal evolution. As a biotechnology company standing at the forefront of the industry, Creative Biolabs is proficient in advanced technologies and the latest methods. We are confident in offering high-quality and comprehensive ctDNA detection services.
A new diagnostic concept referred to as liquid biopsy has received considerable attention over the past years. ctDNA fragments are released by tumor cells into the bloodstream and in principle contain genetic defects identical to the tumor cells they originate from. Evidence indicates that ctDNA provides a comprehensive view of the tumor genome as it reflects DNA released from multiple tumor regions or different tumor foci. A particular advantage of ctDNA as a biomarker is that it might be informative about tumor mass, which reflects the extent of the disease and hence response to a given therapy. ctDNA has been shown to have prognostic value. In addition, identification of tumor-specific changes in ctDNA from blood has also enabled detection of minimal residual disease and prediction of recurrence with lead times of several months in patients with colon, breast, and lung cancer. What's more, ctDNA analysis enables the detection of resistance markers, such as KRAS mutations in patients with colorectal cancer (CRC) receiving anti-EGFR therapy. Together, these features of ctDNA make it a promising analyte for precision oncology applications.
Fig.1 Applications of ctDNA analysis during the course of disease management.
(Wan, 2017)
Technologies for single-locus or multiplexed assays including Microfluidic or allele-specific PCR, enrichment for mutant alleles, allele-specific amplification for companion diagnostics, etc. Varies by method, optimal implementations can reach the sensitivity of 0.001%-0.01% or individual mutant copies per milliliter. These methods have been applied in clinical for detecting and quantifying recurrent hot-spot mutations, monitoring for recurrent resistance mutations, and rapid turnaround time.
Technologies for targeted sequencing approaches including amplicon-based (such as TAm-Seq, enhanced TAm-Seq, and safe-SeqS) and Hybrid Capture (such as exome sequencing, CAPP-Seq, and Digital sequencing). These technologies have been applied in clinical for profiling gene panels, monitoring for de novo resistance mutations, and monitoring clonal evolution in response to therapy.
Technologies for genome-wide assays including whole-genome sequencing such as personalized analysis of rearranged ends (PARE), plasma-Seq and amplicon-based assay such as fast aneuploidy screening test-sequencing system (FAST)-SeqS and modified FAST-SeqS. These technologies have been applied in clinical for identifying structural variants, stratifying patient samples on the basis of disease burden, and detecting the presence of chromosomal aberrations.
Fig.2 Current and future paradigms for the sensitive detection of ctDNA. (Wan, 2017)
Focusing on the research of in vitro diagnostic (IVD) researches over years, Creative Biolabs has established a comprehensive platform with advanced technologies, the latest research methods, and professional experts. With the platform, we have met hundreds of clients' different requirements step-by-step practice has helped us build a great industry reputation and every progress is to give our customers better services.
With rich industrial experience, Creative Biolabs is professional in providing ctDNA detection services and believes that our services are capable of bringing our customers' satisfaction. If you are interested in ctDNA detection services or you have any other questions about our services, please don't hesitate to contact us for more information.
Reference
For Research Use Only.
